This propensity score-matched cohort study used UK general practice records to compare 1-year all-cause mortality after initial tramadol prescription versus five other analgesics in osteoarthritis patients aged 50 and older. The central question: is tramadol — widely recommended and increasingly prescribed — actually safer than alternatives, or does its use track with higher mortality?
When you write a tramadol prescription for a knee OA patient, you're following guideline-supported practice. Both AAOS and ACR recommendations endorsed tramadol at the time of this study. This paper asks whether that recommendation is safe.
The association with higher mortality than all four NSAIDs studied is real, consistent across six sensitivity analyses, and clinically meaningful in magnitude. However, causality is not established. Tramadol users were sicker before matching, and unmeasured confounders — pain severity, frailty, functional decline — could plausibly explain part or all of the difference.
The codeine comparison is the most useful clinical anchor. Tramadol and codeine had equivalent mortality (HR 0.94). If you're choosing tramadol because you believe it's a safer opioid than alternatives, this finding does not support that belief. The opioid class risk appears to be the issue, not something unique to tramadol.
For practice: in elderly OA patients with manageable GI and CV risk profiles, NSAIDs (with appropriate gastroprotection) carry a lower observed mortality signal than tramadol in this dataset. Non-opioid therapy should be exhausted before reaching for tramadol, particularly given that tramadol provides no demonstrable pain relief advantage over NSAIDs.
This propensity score-matched cohort study used UK general practice records to compare 1-year all-cause mortality after initial tramadol prescription versus five other analgesics in osteoarthritis patients aged 50 and older. The central question: is tramadol — widely recommended and increasingly prescribed — actually safer than alternatives, or does its use track with higher mortality?
When you write a tramadol prescription for a knee OA patient, you're following guideline-supported practice. Both AAOS and ACR recommendations endorsed tramadol at the time of this study. This paper asks whether that recommendation is safe.
The association with higher mortality than all four NSAIDs studied is real, consistent across six sensitivity analyses, and clinically meaningful in magnitude. However, causality is not established. Tramadol users were sicker before matching, and unmeasured confounders — pain severity, frailty, functional decline — could plausibly explain part or all of the difference.
The codeine comparison is the most useful clinical anchor. Tramadol and codeine had equivalent mortality (HR 0.94). If you're choosing tramadol because you believe it's a safer opioid than alternatives, this finding does not support that belief. The opioid class risk appears to be the issue, not something unique to tramadol.
For practice: in elderly OA patients with manageable GI and CV risk profiles, NSAIDs (with appropriate gastroprotection) carry a lower observed mortality signal than tramadol in this dataset. Non-opioid therapy should be exhausted before reaching for tramadol, particularly given that tramadol provides no demonstrable pain relief advantage over NSAIDs.